NEW YORK — MiniMed Group Inc. shares jumped more than 11% on Wednesday, reaching $13.69 as investors responded positively to the diabetes technology company's strong fourth-quarter and full-year 2026 financial results, along with an optimistic outlook for the coming year.

The medical device firm, which was spun out from Medtronic earlier this year, reported robust revenue growth and progress in its automated insulin delivery systems. The gains pushed MiniMed's market capitalization higher amid renewed interest in diabetes care stocks following positive clinical data and product pipeline updates.

For the full fiscal year 2026, MiniMed delivered revenue of approximately $3.1 billion, reflecting solid demand for its MiniMed 780G automated insulin delivery system and related sensors. The company highlighted strong adoption of its integrated pump and continuous glucose monitoring solutions, particularly in key markets across North America and Europe.

In the fourth quarter, MiniMed posted revenue growth driven by higher sales of consumables and new system launches. While the company still reported a net loss, operational improvements and cost management helped narrow the deficit compared to prior periods. Management emphasized expanding gross margins and operational efficiency as key priorities following the spin-off.

MiniMed also announced plans to expand its sensor portfolio through a collaboration with Abbott for integrated dual glucose-ketone sensors. This development is expected to strengthen its competitive position in the growing automated insulin delivery market.

Analysts have largely welcomed the results. Several........

© International Business Times